Small cell lung cancer · line 2 · Tarlatamab — 2L+ extensive-stage SCLC (DeLLphi-301; DLL3 × CD3 BiTE)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-TARLATAMAB |
| ID | IND-SCLC-RR-TARLATAMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-SCLC |
| Sources | SRC-DELLPHI-301-AHN-2023 SRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for R/R ES-SCLC after platinum-based 1L chemotherapy. No biomarker dependency for label use (DLL3 IHC NOT required); applicability driven by line-of-therapy + ECOG + organ function + access to inpatient infusion centre. Mandatory cycle 1 inpatient monitoring (≥22 hr post D1 + D8) + tocilizumab-on-formulary + ICU access for Grade ≥3 CRS are structural deployment constraints beyond drug acquisition cost. Ukraine access constraint dominant (not registered, not НСЗУ; out-of-pocket USD 30-40K/cycle) AND structural infrastructure barrier limits realistic deployment. Evidence level: moderate (single-arm phase 2 + FDA accelerated approval; phase 3 DeLLphi-304 confirmatory trial pending); strength of recommendation: conditional. Algorithm wiring deferred — SCLC R/R algorithm not yet authored in KB; out of chunk scope. PUL-A4 chunk closes #491.
Used By
Algorithms
ALGO-SCLC-2L- ALGO-SCLC-2L